atoms

SymBio Pharmaceuticals

TYO: 4582

JPY14424.4m market cap

JPY410 last close

SymBio is a Japanese specialty pharma company with a focus on oncology and haematology. Treakisym is SymBio’s branded formulation of bendamustine HCl. Rigosertib was in-licensed from Onconova and brincidofovir was licensed from Chimerix in 2019.

Investment summary

SymBio is a speciality pharma focused on Asia-Pacific markets and has in-licensed two orphan blood cancer products. Treakisym iv was approved for r/r low-grade NHL/MCL in 2010 and in 2016 for CLL and first-line low-grade NHL/MCL. SymBio has in-licensed liquid formulations for injection that will give Treakisym patent protection to 2031; a clinical trial is underway of the rapid-infusion liquid formulation that would reduce Treakisym infusion time from 60 minutes to 10. A Phase III trial of Treakisym in r/r diffuse large B-cell lymphoma recently reported positive results and the company has filed for a label extension. Rigosertib iv is in development for r/r HR-MDS and is in a pivotal Phase III global study in 360 patients; SymBio is enrolling patients in Japan and aims for potential filing in 2021. It intends to participate in a planned global trial of high-dose oral rigosertib in untreated HR-MDS. It in-licensed the antiviral brincidofovir from Chimerix in September 2019.

Y/E Dec
Revenue (¥m)
EBITDA (¥m)
PBT (¥m)
EPS (fd) (¥)
P/E (x)
P/CF (x)
2018A 3836.0 (2621.0) (2749.0) (165.5) N/A N/A
2019A 2838.0 (4264.0) (4377.0) (189.2) N/A N/A
2020E 2608.0 (5179.0) (5256.0) (181.4) N/A N/A
2021E 9228.0 1165.0 1090.0 18.9 2169.3 127.1
Industry outlook

SymBio is focused on in-licensing niche opportunities in hard-to-treat indications often overlooked by big pharma. An in-house screening process to select additional pipeline candidates for development and commercialisation will be key to driving operational leverage.

Last updated on 06/08/2020
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (¥m) 1875
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (14.2) 6.8 (31.1)
Relative* (12.7) (1.4) (33.3)
52-week high/low ¥791.0/¥264.0
*% relative to local index
Key management
Fuminori Yoshida Representative Director, President & CEO
Kenji Murata Corporate Officer

Content on SymBio Pharmaceuticals